| Budget Amount *help |
¥18,720,000 (Direct Cost: ¥14,400,000、Indirect Cost: ¥4,320,000)
Fiscal Year 2015: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥9,880,000 (Direct Cost: ¥7,600,000、Indirect Cost: ¥2,280,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we investigated role of HMGB1 for regulating cutaneous homeostasis, and possibility of HMGB1 application for treating intractable skin diseases. In summary, we clarified following mechanisms; 1) necrotic tissue-derived HMGB1 binds to proteoglycan "syndecan" to be pooled on the cell surface and released when injury occurs, 2) released HMGB1 in the circulation binds to the receptor on the cell membrane of bone marrow mesenchymal stem cells (MSCs) and mobilize them into the circulation, 3) the mobilized MSCs in the circulation target the injured/necrotic tissues by SDF-1/CXCR4 axis generated on the vascular endothelial cell surface, and 4) the mobilized MSCs in the injured tissue then suppress inflammation, reduce scar formation, and induce tissue regeneration.
|
